Pharmacotherapy of systemic sclerosis.

Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum (2011) 1.51

Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res (2011) 0.93

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther (2014) 0.90

Pathogenesis of Systemic Sclerosis. Front Immunol (2015) 0.89

CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther (2012) 0.82

Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Res Ther (2014) 0.78

Cellular Therapies in Systemic Sclerosis: Recent Progress. Curr Rheumatol Rep (2016) 0.75

Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med (1969) 4.76

Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med (2006) 4.46

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91

Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46

Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80

Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest (1987) 2.74

Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum (2006) 2.72

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol (2006) 2.42

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 2.26

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation (2005) 2.25

The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol (1998) 1.97

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum (2001) 1.96

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood (2007) 1.95

Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther (2005) 1.81

Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest (1992) 1.79

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest (2004) 1.72

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ (1989) 1.70

B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol (2006) 1.64

Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum (2007) 1.62

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol (2009) 1.60

Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum (2006) 1.60

A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol (2006) 1.54

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med (1994) 1.50

Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol (2008) 1.47

Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther (2006) 1.46

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol (2007) 1.46

A cohort study of cancer incidence in systemic sclerosis. J Rheumatol (2006) 1.39

The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol (2001) 1.33

Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum (2000) 1.33

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum (2008) 1.29

Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007) 1.27

The heart in scleroderma. Rheum Dis Clin North Am (2008) 1.26

CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology (2004) 1.25

Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol (2009) 1.20

Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum (2008) 1.20

Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem (1995) 1.20

Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18

Renal complications and scleroderma renal crisis. Rheumatology (Oxford) (2009) 1.17

Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol (1990) 1.17

Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) (2006) 1.17

Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum (2006) 1.16

Cardiac complications of systemic sclerosis. Rheumatology (Oxford) (2009) 1.16

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med (2006) 1.14

Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci (2009) 1.13

Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol (2005) 1.13

Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum (2008) 1.13

Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum (2002) 1.09

Benign persistent pneumoperitoneum in scleroderma. Dig Dis Sci (1986) 1.09

Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum (2007) 1.08

Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) (2009) 1.07

Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol (2006) 1.07

Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. Rheumatology (Oxford) (2008) 1.07

Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol (2007) 1.06

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum (1998) 1.05

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum (2007) 1.05

Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum (2005) 1.03

Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol (2005) 1.03

Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol (1998) 1.02

Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest (1991) 1.01

Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis (2006) 1.00

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol (1998) 0.98

Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) (2005) 0.97

Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol (1999) 0.97

Human mast cells release Interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy (2005) 0.96

Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol (1996) 0.95

Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol (2006) 0.95

IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol (1996) 0.95

Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) (2009) 0.95

Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol (2009) 0.94

Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol (2008) 0.93

Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol (2008) 0.93

Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev (2002) 0.93

Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol (1993) 0.92

The possible role of myocardial biopsy in systemic sclerosis. Rheumatology (Oxford) (2000) 0.92

Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum (1998) 0.92

Expression of stem cell factor in the lesional skin of systemic sclerosis. Dermatology (1998) 0.91

Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol (1993) 0.91

Targeted therapy comes of age in scleroderma. Trends Immunol (2005) 0.91

The heart in systemic sclerosis. Curr Rheumatol Rep (2004) 0.90

Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum (2003) 0.90

Antimyenteric neuronal antibodies in scleroderma. J Clin Invest (1994) 0.90

Abnormal colonic motility in progressive systemic sclerosis. Ann Intern Med (1981) 0.90

Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut (2002) 0.89

Role of cellular immunity in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol (2006) 0.89

Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol (2008) 0.89

Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum (2009) 0.88

Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis (2006) 0.88

Human mast cells release oncostatin M on contact with activated T cells: possible biologic relevance. J Allergy Clin Immunol (2007) 0.87

Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann Rheum Dis (2006) 0.85

Anorectal dysfunction and delayed colonic transit in patients with progressive systemic sclerosis. Dig Dis Sci (1993) 0.85

Significance of microparticles in progressive systemic sclerosis with interstitial pneumonia. Platelets (2008) 0.85

Transverse colon volvulus associated with scleroderma. Am J Surg (1977) 0.81

Stercoral ulceration and perforation of the sclerodermatous colon: report of two cases and review of the literature. Dis Colon Rectum (1974) 0.81

Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med (2012) 3.85

Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol (2008) 0.99

A retrospective review of lower extremity fracture care in patients with spinal cord injury. J Spinal Cord Med (2013) 0.92

The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med (2013) 0.84

The association of anticonvulsant use with fractures in spinal cord injury. Am J Phys Med Rehabil (2013) 0.78